. 2024 Feb 7;6(2):e1026. doi: 10.1097/CCE.0000000000001026

TABLE 2.

Selected Characteristics of Patients, Including Selected Emergency Department Interventions, by Interpretation Band

Category	Subcategory	Interpretation Band			p
Category	Subcategory	Band 1, n = 252	Band 2, n = 160	Band 3, n = 160	p
Age	Median (Q1–Q3)	54.0 (39.8–67.0)^a,b	56.0 (39.0–68.0)^a,c	58.00 (41.8–71.0)^b,c	ns^a, ns^b, ns^c
Age	≥ 65, n (%)	77 (30.6)^a,b	54 (33.8)^a,c	56 (35.0)^b,c	ns^a, ns^b, ns^c
Biological sex, n (%)	Male	146 (57.9)^a,b	92 (57.5)^a,c	84 (52.5)^b,c	ns^a, ns^b, ns^c
Biological sex, n (%)	Female	106 (42.1)^a,b	68 (42.5)^a,c	76 (47.5)^b,c	ns^a, ns^b, ns^c
Race, n (%)	Black or African American	76 (30.2)^a,b	47 (29.4)^a,c	49 (30.6)^b,c	ns^a, ns^b, ns^c
	White	154 (61.1)^a,b	104 (65.0)^a,c	98 (61.3)^b,c	ns^a, ns^b, ns^c
	Other	22 (8.7)^a,b	9 (5.6)^a,c	13 (8.1)^b,c	ns^a, ns^b, ns^c
Comorbidities, n (%)	Autoimmune disease	9 (3.6)^a,b	7 (4.4)^a,c	7 (4.4)^b,c	ns^a, ns^b, ns^c
	Diabetes	71 (28.2)^a,b	40 (25.0)^a,c	54 (33.8)^b,c	ns^a, ns^b, ns^c
	HIV	2 (0.8)^a,b	3 (1.9)^a,c	6 (3.8)^b,c	ns^a, p < 0.05^b, ns^c
	Hepatitis C	20 (7.9)^a,b	11 (6.9)^a,c	15 (9.4)^b,c	ns^a, ns^b, ns^c
	Hypertension	121 (48.0)^a,b	82 (51.3)^a,c	87 (54.4)^b,c	ns^a, ns^b, ns^c
	Obesity	44 (17.5)^a,b	32 (20.0)^a,c	22 (13.8)^b,c	ns^a, ns^b, ns^c
	End-stage renal disease	6 (2.4)^a,b	9 (5.6)^a,c	3 (1.9)^b,c	ns^a, ns^b, ns^c
Outpatient medications, n (%)	Antibiotics	30 (11.9)^a,b	17 (10.6)^a,c	20 (12.5)^b,c	ns^a, ns^b, ns^c
	Anti-inflammatory	79 (31.3)^a,b	45 (28.1)^a,c	55 (28.1)^b,c	ns^a, ns^b, ns^c
	Corticosteroids	18 (7.1)^a,b	10 (6.3)^a,c	13 (8.1)^b,c	ns^a, ns^b, ns^c
Adjudicated sepsis-3	Yes	28 (11.1)^a,b	45 (28.1)^a,c	79 (49.4)^b,c	p < 0.0001^a, p < 0.0001^b, p < 0.0001^c
Sepsis adjudication, n (%)	Unanimous	206 (81.8)^a,b	120 (75.0)^a,c	124 (77.5)^b,c	ns^a, ns^b, ns^c
	Consensus	44 (17.5)^a,b	40 (25.0)^a,c	36 (22.5)^b,c	ns^a, ns^b, ns^c
	Forced	2 (0.8)^a,b	0 (0.0)^a,c	0 (0.0)^b,c	ns^a, ns^b, ns^c
WBC (10³ cells/µL), median (Q1–Q3)		8.9 (6.7–12.9)^a,b	12.6 (9.4–15.7)^a,c	15.7 (11.8–19.1)^b,c	p < 0.0001^a, p < 0.0001^b, p < 0.0001^c
Lactate measured, n (%)	Yes	93 (36.9)^a,b	91 (56.9)^a,c	110 (68.8)^b,c	p < 0.0001^a, p < 0.0001^b, p < 0.05^c
Lactate, median (Q1–Q3)		1.6 (1.2–2.6)^a,b	1.6 (1.2–2.7)^a,c	1.8 (1.3–2.6)^b,c	ns^a, ns^b, ns^c
IntelliSep Index, median (Q1–Q3)		4.0 (3.3–4.4)^a,b	5.5 (5.2–5.9)^a,c	7.4 (6.7–7.9)^b,c	p < 0.0001^a, p < 0.0001^b, p < 0.0001^c

ns = not significant, Q1–Q3 = interquartile range.

Cancer refers to those with history or current cancer that did not meet the study exclusion criteria of history of hematologic malignancies, and/or receipt of cytotoxic chemotherapy within 3 months of the emergency department encounter. “Anti-inflammatory” outpatient medications included acetaminophen (Tylenol), celecoxib (Celebrex), ibuprofen (Advil), indomethacin (Indocin), and naproxen (Aleve). S1-Table 2 (http://links.lww.com/CCX/B289) contains the complete table of characteristics.